---
layout: post
title: "Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment; Availability"
date: 2026-02-05 18:55:17 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-08331
original_published: 2023-04-20 00:00:00 +0000
significance: 8.00
---

# Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 20, 2023 00:00 UTC
**Document Number:** 2023-08331

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment." The purpose of this draft guidance is to provide information and recommendations to assist sponsors and other interested parties in the development of drugs to prevent or treat acute radiation syndrome (ARS) caused by exposure to ionizing radiation from accidental or deliberate events. Generally, drugs developed for such indications will require approval under the regulations commonly referred to as the Animal Rule.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/20/2023-08331/acute-radiation-syndrome-developing-drugs-for-prevention-and-treatment-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-08331

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
